NCT01787994View on ClinicalTrials.gov

Redirected MazF-CD4 Autologous T Cells for HIV Gene Therapy

PHASE1CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

December 31, 2012

Primary Completion Date

July 31, 2017

Study Completion Date

July 31, 2017

Conditions
HIV
Interventions
GENETIC

Autologous CD4+ T cells genetically modified with a retroviral vector expressing the MazF endoribonuclease gene (MazF-T), given via intravenous infusion.

Trial Locations (1)

19102

Division of Infectious Diseases & HIV Medicine at Drexel University College of Medicine, Philadelphia

All Listed Sponsors
lead

University of Pennsylvania

OTHER

NCT01787994 - Redirected MazF-CD4 Autologous T Cells for HIV Gene Therapy | Biotech Hunter | Biotech Hunter